This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Questions about our CME?
Questions about our CME?

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

New Insights on the Role of Janus Kinase (JAK) Inhibition in Rheumatoid Arthritis and <em>"Do You Know JAK?"</em> Interactive Game

New Insights on the Role of Janus Kinase (JAK) Inhibition in Rheumatoid Arthritis and "Do You Know JAK?" Interactive Game

Format

Roundtable

Time to Complete

1 hour

Released

August 25, 2017

Expires

August 25, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



This activity is provided by Paradigm Medical Communications, LLC.

Commercial Supporter

This activity is supported by an educational grant from Pfizer Inc.

Program Description

Rheumatoid arthritis (RA) is the most common inflammatory arthritis in adults. Janus kinases (JAKs) are central to the destructive immune and inflammatory responses implicated in the pathogenesis of RA. In this activity, the expert faculty, Dr. Roy Fleischmann, Dr. Allan Gibofsky and Dr. Joseph Markenson, will provide a primer on the role of JAKs in the pathophysiology of RA and the clinical use of JAK inhibitors.

You will have an opportunity to test your knowledge of JAKs, JAK inhibitors, and their use in the treatment of RA in the interactive “Do You Know JAK?” game. The object of the game is to successfully inhibit the progress of RA through correctly answering questions about the disease, the inflammatory pathways, and therapeutic options for treatment. Correct answers will result in successful JAK inhibition and reduction of inflammation, while incorrect answers will show no change. These exercises will be followed by a roundtable discussion with the faculty highlighting the unique features of JAK inhibition in RA.

Intended Audience

This activity has been designed to address the educational needs of physicians specializing in rheumatology. It may also benefit nurses, nurse practitioners, PAs, and other members of the multidisciplinary team who care for patients with RA.

Educational Objectives

Upon proper completion of this activity, participants should be better able to:

  • Describe the role of Janus kinase (JAK) in the chronic cycle of inflammation associated with RA
  • Identify the intracellular immune and anti-inflammatory effects of JAK inhibition on RA
  • Select appropriate candidates for treatment of RA with JAK inhibitors

Conflict Of Interest Disclosure Policy

Paradigm Medical Communications, LLC, has implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Faculty

The faculty reported the following financial relationships or relationships to products or devices, they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Roy Fleischmann, MD, MACR
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Co-Medical Director
Metroplex Clinical Research Center
Dallas, TX

Dr. Fleischmann discloses the following:
Advisory Boards: AbbVie Inc., Eli Lilly and Company, Pfizer Inc.
Speakers' Bureau: Pfizer Inc.
Clinical Trials: AbbVie Inc., Eli Lilly and Company, Pfizer Inc.

Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, NY

Dr. Gibofsky discloses the following:
Consulting Fees: AbbVie Inc., Eli Lilly and Company, Merck & Co., Inc, Pfizer Inc
Speakers' Bureau: AbbVie Inc., Celgene Corporation, Horizon Pharma plc, Novartis Pharmaceuticals Corporation,
Pfizer Inc
Stockholder (Self and Spouse): AbbVie Inc., Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Pfizer Inc, Regeneron Pharmaceuticals, Inc

Joseph A. Markenson, MD, MACP, FACP
Clinical Professor of Medicine
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, NY

Dr. Markenson discloses the following:
Consulting Fees: Celgene Corporation Eli Lilly and Company, Merck & Co., Inc
Fees for non-CME Services: Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck & Co., Inc, Pfizer Inc

Accredited Provider Disclosure

Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Credit Information

PA Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Instructions

To receive a CME certificate of participation, you should:

  • Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pretest.
  • View the online activity in its entirety.
  • Complete and submit the online post-test and evaluation. You must answer 70% of the post-test questions correctly to earn credit. You will have unlimited opportunities to successfully complete the post-test.
A certificate of participation will be available for download/printing immediately following your successful completion of the post-test and evaluation. Your certificate will be saved on the Paradigm Medical Communications website and will not be available in your myCME CME History.

There is no fee required for participation in this activity.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

Technical Support: If you have any technical problems or playback issues, please email Paradigm at contactus@paradigmmc.com.

Privacy Policy

Paradigm is committed to protecting the privacy of those who participate in the activities (herein referred to as “website”) located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm will not otherwise disclose personal information unless required to in a legal process. Paradigm staff members review individual test results to the extent necessary to record and track participants’ credits.

Paradigm Medical Communications, LLC, privacy policy

myCME privacy policy

System Requirements

This certified CME activity is designed using HTML5 audio and video.

For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Copyright

© 2017 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
Add to Queue